Homozygous A polymorphism of the complement C1qA276 correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP
Journal of Hematology & Oncology, 08/17/2012
Clinical Article
Jin X et al. – The results suggest that C1qA polymorphism may be a biomarker to predict response to RCHOP as frontline therapy for diffuse large B cell lymphoma (DLBCL) patients.



